RxDoctor Payments Data

Barbara Holdren

Family · Meadowbrook, PANPI 1417019985

Payments from drug & device makers

$681in general payments, 2019–2025

Across 33 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$247
  • Pfizer$87
  • GSK$80
  • Lilly USA, LLC$65
  • Boehringer Ingelheim$46
  • Dexcom, Inc.$39
  • plus $117 from 5 others

What the payments were for

  • Food & beverage$681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$681 in reported general payments places this provider in the 65th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$19,606
Medicare patients
152
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$42,043
FarxigaDapagliflozin Propanediol19$29,545
AbrysvoRsv Vacc, Pref A And Pref B/Pf74$23,462
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$22,597
OzempicSemaglutide12$20,634
TrulicityDulaglutide24$18,791
JardianceEmpagliflozin11$16,153
MounjaroTirzepatide15$15,409
LinzessLinaclotide12$6,906
Breo ElliptaFluticasone/Vilanterol14$5,482
Atorvastatin Calcium387$5,294
Losartan Potassium241$4,252
Levothyroxine Sodium223$3,109
Metoprolol Succinate147$2,800
Rosuvastatin Calcium92$2,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$87$65,504117 claims
Lilly USA, LLCTrulicity, Mounjaro$65$34,20039 claims
AstraZenecaFarxiga$15$29,54519 claims
GSKTrelegy Ellipta, Breo Ellipta$80$28,07837 claims
Novo NordiskOzempic$36$20,63412 claims
Boehringer IngelheimJardiance$46$16,15311 claims
AbbVieLinzess, Synthroid$247$9,40760 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,717 family providers in Pennsylvania.

Other family in Meadowbrook

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →